Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Carcinogenic effects of "whole-life" exposure to inorganic arsenic in CD1 mice.

Tokar EJ, Diwan BA, Ward JM, Delker DA, Waalkes MP.

Toxicol Sci. 2011 Jan;119(1):73-83. doi: 10.1093/toxsci/kfq315. Epub 2010 Oct 11.

2.

Lung tumors in mice induced by "whole-life" inorganic arsenic exposure at human-relevant doses.

Waalkes MP, Qu W, Tokar EJ, Kissling GE, Dixon D.

Arch Toxicol. 2014 Aug;88(8):1619-29. doi: 10.1007/s00204-014-1305-8. Epub 2014 Jul 9.

3.

Mechanisms underlying arsenic carcinogenesis: hypersensitivity of mice exposed to inorganic arsenic during gestation.

Waalkes MP, Liu J, Ward JM, Diwan BA.

Toxicology. 2004 May 20;198(1-3):31-8.

PMID:
15138027
4.
5.

Impact of life stage and duration of exposure on arsenic-induced proliferative lesions and neoplasia in C3H mice.

Ahlborn GJ, Nelson GM, Grindstaff RD, Waalkes MP, Diwan BA, Allen JW, Kitchin KT, Preston RJ, Hernandez-Zavala A, Adair B, Thomas DJ, Delker DA.

Toxicology. 2009 Aug 3;262(2):106-13. doi: 10.1016/j.tox.2009.05.003. Epub 2009 May 18.

6.
7.

Tumors and proliferative lesions in adult offspring after maternal exposure to methylarsonous acid during gestation in CD1 mice.

Tokar EJ, Diwan BA, Thomas DJ, Waalkes MP.

Arch Toxicol. 2012 Jun;86(6):975-82. doi: 10.1007/s00204-012-0820-8. Epub 2012 Mar 8.

8.

Transplacental arsenic carcinogenesis in mice.

Waalkes MP, Liu J, Diwan BA.

Toxicol Appl Pharmacol. 2007 Aug 1;222(3):271-80. Epub 2007 Jan 12.

9.

Animal models for arsenic carcinogenesis: inorganic arsenic is a transplacental carcinogen in mice.

Waalkes MP, Liu J, Ward JM, Diwan BA.

Toxicol Appl Pharmacol. 2004 Aug 1;198(3):377-84.

PMID:
15276417
10.

Arsenic exposure in utero and nonepidermal proliferative response in adulthood in Tg.AC mice.

Tokar EJ, Diwan BA, Waalkes MP.

Int J Toxicol. 2010 May-Jun;29(3):291-6. doi: 10.1177/1091581810362804.

PMID:
20448261
11.

Arsenic, stem cells, and the developmental basis of adult cancer.

Tokar EJ, Qu W, Waalkes MP.

Toxicol Sci. 2011 Mar;120 Suppl 1:S192-203. doi: 10.1093/toxsci/kfq342. Epub 2010 Nov 11.

13.

Effects of in Utero Exposure to Arsenic during the Second Half of Gestation on Reproductive End Points and Metabolic Parameters in Female CD-1 Mice.

Rodriguez KF, Ungewitter EK, Crespo-Mejias Y, Liu C, Nicol B, Kissling GE, Yao HH.

Environ Health Perspect. 2016 Mar;124(3):336-43. doi: 10.1289/ehp.1509703. Epub 2015 Aug 21.

14.
15.
16.

Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen.

Waalkes MP, Liu J, Ward JM, Diwan BA.

Toxicol Appl Pharmacol. 2006 Sep 15;215(3):295-305. Epub 2006 May 18.

PMID:
16712894
17.

Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation.

Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP.

Toxicol Appl Pharmacol. 2001 Sep 15;175(3):260-8.

PMID:
11559025
18.
19.

Folate deficiency enhances arsenic effects on expression of genes involved in epidermal differentiation in transgenic K6/ODC mouse skin.

Nelson GM, Ahlborn GJ, Delker DA, Kitchin KT, O'Brien TG, Chen Y, Kohan MJ, Roop BC, Ward WO, Allen JW.

Toxicology. 2007 Nov 30;241(3):134-45. Epub 2007 Sep 1.

PMID:
17928125
20.

Toxicology and carcinogenesis studies of o-nitrotoluene sulfone (CAS no. 88-72-2) in F344/N rats and B6C3F(1) mice (feed studies).

National Toxicology Program, Public Health Service, National Institutes of Health, US Department of Health and Human Services..

Natl Toxicol Program Tech Rep Ser. 2002 May;(504):1-357.

Supplemental Content

Support Center